The funding landscape is currently defined by an extreme concentration of wealth. While 28 rounds were logged, a single seed-stage AI lab has effectively out-raised the combined totals of multiple sectors, putting immense pressure on non-AI founders to justify their valuations.
This disparity creates a high-risk environment where Robotics is left with $0 and Defense is squeezed into a single $10M round. The gap between the AI peak and the rest of the market has never been sharper.
The Capital Divide
AI leads the pack with 13 rounds totaling $1.1B, driven largely by the outlier success of Flapping Airplanes. Health follows with significant momentum, securing $517M across just 3 rounds, signaling a strong preference for high-conviction, deep-tech bets over broad diversification.
The Funding Hierarchy
- Year-old AI lab Flapping Airplanes: $1B
- Oxford spin-out OMass Therapeutics: €275 million
- Pigment: $250m
- Cell-Specific RNA Delivery Firm Soufflé: $135M
- Nouscom: €120 million
What founders can do
- AI Founders: Leverage the current seed-stage appetite for massive checks to secure longer runways before the market corrects.
- Health Founders: Focus on Series C and B scaling, as high-value rounds like those for OMass and Soufflé show strong late-stage appetite.
- Defense and Robotics Founders: Diversify funding sources beyond traditional VC, as current logged data shows a stark lack of institutional capital in these sectors.